1.首都医科大学附属北京中医医院肿瘤科,北京 0000
2.首都医科大学,北京 100069
刘梓燊(1995年生),女;研究方向:中西医结合肿瘤;E-mail:liuzishen1001@163.com
杨国旺(1969年生),男;研究方向:中西医结合肿瘤;E-mail:guowangyang@sina.com
纸质出版日期:2020-09-25,
收稿日期:2020-04-26,
扫 描 看 全 文
刘梓燊,杨国旺.基于网络药理学分析“黄芪―白术”治疗肺癌的作用机制[J].中山大学学报(自然科学版),2020,59(05):134-143.
LIU Zishen,YANG Guowang.Mechanisms of “Astragalus membranaceus - Atractylodes macrocephala koidz” for the treatment of lung cancer based on network pharmacology[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2020,59(05):134-143.
刘梓燊,杨国旺.基于网络药理学分析“黄芪―白术”治疗肺癌的作用机制[J].中山大学学报(自然科学版),2020,59(05):134-143. DOI: 10.13471/j.cnki.acta.snus.2020.04.26.2020E012.
LIU Zishen,YANG Guowang.Mechanisms of “Astragalus membranaceus - Atractylodes macrocephala koidz” for the treatment of lung cancer based on network pharmacology[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2020,59(05):134-143. DOI: 10.13471/j.cnki.acta.snus.2020.04.26.2020E012.
通过网络药理学的研究方法,探索“黄芪―白术”治疗肺癌的可能作用机制。使用中药系统药理学分析平台(TCMSP)数据库查询“黄芪―白术”的活性成分,运用TCMSP数据库对活性成分的靶点进行筛选,并利用Uniprot数据库对靶点进行标准化命名。通过“TTD”数据库、“DisGeNET”数据库和“OMIM”数据库查询肺癌相关靶点。利用Venn Diagram得到“化合物―疾病”共同靶点。运用STRING数据库进行蛋白质互作网络(PPI)的构建。使用R语言进行GO富集分析和KEGG通路富集分析。“黄芪―白术”药对共筛选得到活性成分19个,潜在作用靶点180个。治疗肺癌的预测靶点29个,主要涉及AKT1、VEGFA、EGFR等。GO功能富集分析,按照
P
<0.05进行筛选,涉及生物过程1 260个,细胞组分12个,分子功能32个,主要涉及活性氧代谢过程、类固醇激素反应、凋亡信号通路的调控、T细胞活化等。KEGG信号通路富集分析,按照
P
<0.05进行筛选,涉及信号通路26个,主要涉及PI3K-Akt信号通路、EGFR酪氨酸激酶抑制剂耐药性、铂类耐药性、HIF-1信号通路、MAPK信号通路、Rap1信号通路、Ras信号通路等。“黄芪―白术”通过调控信号通路、抗癌药物耐药性等发挥抑制肿瘤血管生成、诱导肿瘤细胞凋亡、抑制肿瘤转移等作用,从而治疗肺癌。“黄芪―白术”在治疗肺癌的过程中涉及到多活性成分、多靶点及多信号通路。
The study aimed to explore the possible mechanism of “
Astragalus membranaceus - Atractylodes macrocephala
koidz” for the treatment of lung cancer through network pharmacology.The active ingredients of “
Astragalus membranaceus - Atractylodes macrocephala
koidz ” were queried through the TCMSP database
the targets of the active ingredients were screened through the TCMSP database
and the targets were standardized and named through the Uniprot database. The lung cancer related targets were queried through the “TTD” database
“DisGeNET” database and “OMIM” database. The “compound-disease” common targets were obtained using Venn Diagram
and the protein interaction network (PPI) was constructed using STRING database
and R language was used for GO enrichment analysis and KEGG pathway enrichment analysis.“
Astragalus membranaceus-Atractylodes macrocephala
koidz” drugs were screened to obtain 19 active ingredients
180 potential targets
29 potential targets for the treatment of lung cancer
including AKT1
VEGFA
EDFR
etc. GO functional enrichment was analyzed and screened according to
P
<
0.05
which involved 1 260 biological processes
12 cell groups
32 molecular functions
such as reactive oxygen species metabolic process
response to steroid hormone
regulation of apoptotic signaling pathway
T cell activation
etc. KEGG signal pathway enrichment was analyzed and screened according to
P
<
0.05
involving 26 signal pathways
including PI3K-Akt signaling pathway
EGFR tyrosine kinase inhibitor resistance
Platinum drug resistance
HIF-1 signaling pathway
MAPK signaling pathway
Cellular senescence
Rap1 signaling pathway
Ras signaling pathway
etc."
Astragalus membranaceus - Atractylodes macrocephala
koidz " plays a role in inhibiting tumor angiogenesis
inducing tumor cell apoptosis and inhibiting tumor metastasis by regulating signaling pathways and anti-cancer drug resistance
thereby treating lung cancer. “
Astragalus membranaceus-Atractylodes macrocephala
koidz” involves multiple active ingredients
multiple targets and multiple signaling pathways in the treatment of lung cancer.
网络药理学肺癌黄芪―白术作用机制
network pharmacologylung cancerAstragalus membranaceus - Atractylodes macrocephala koidzmechanism of action
BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancerstatistics2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
国家卫生健康委员会.中国卫生健康统计年鉴2018[M].北京:中国协和医科大学出版社,2014:271-272.
梁姗姗,张玉,张青.郁仁存治疗非小细胞肺癌经验[J].中医学报,2018,33(2):200-203.
LIANG S S, ZHANG Y, ZHANG Q. Professor Yu Renqun's experience in the treatment of non-small cell lung cancer[J].Acta Chinese Medicine,2018,33(2):200-203.
容志航.北京市名老中医治疗肺癌的经验总结与临床研究[D].北京:北京中医药大学,2013.
RONG Z H.The experience summary and clinical research of the eminent and experience Chinese Medicine Practitioners in Beijing in treating lung cancer[D].Beijing:Beijing University of Chinese Medicine,2013.
杜秀婷,刘鹏,刘柏,等.原发性支气管肺癌中医证型与病理类型的相关性研究[J].中医药导报,2019,25(24):18-21+25.
DU X T,LIU P,LIU B,et al.Correlation Study on histopathologic types and traditional Chinese Medicine syndromes in primary lung cancer[J].Guiding Journal of Traditional Chinese Medicine and Pharmacy,2019,25(24):18-21+25.
周萍,周滢.黄芪与白术的配伍机制及临床应用浅析[J].中国实验方剂学杂志,2012,18(17):261-263.
ZHOU P,ZHOU Y.Analysis of compatible mechanism of Astragalus membranaceus and Atractylodes macrocephala and clinical application[J].Chinese Journal of Experimental Traditional Medical Formulae,2012,18(17):261-263.
吴璐璐,王佳春,袁昌劲.基于关联规则的晚期肺癌中医用药规律分析[J].肿瘤药学,2019,9(3):494-498.
WU L L,WANG J C,YUAN C J.Analysis on the regularity of traditional Chinese Medicine for advanced lung cancer based on association rules[J].Anti-tumor Pharmacy,2019,9(3):494-498.
周伟鹤.基于数据挖掘技术肺癌中医药治疗用药特点、规律总结及实验验证[D].济南:山东大学,2018.
ZHOU W H.The treatment characteristics,summarize the rule and the experimental verification of traditional Chinese medicine based on data mining technology in lung cancer[D].Jinan:Shandong University,2018.
LEI C S,HOU Y C,PAI M H,et al.Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells:in vitro and in vivo studies[J].Journal of nutritional biochemistry,2018,51:105-113.
LI H,TAN L,ZHANG J W,et al.Quercetin is the Active Component of Yang-Yin-Qing-Fei-Tang to Induce Apoptosis in Non-Small Cell Lung Cancer[J].American Journal of Chinese Medicine,2019,47(4):879-893.
WU L W,LI J J,LIU T,et al.Quercetin shows anti‐tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway[J].Cancer Medicine,2019,8(10):4806-4820.
赵欣,张健.槲皮素抑制肺癌肿瘤细胞的生长和转移的机制[J].中南大学学报(医学版),2015,40(6):592-597.
ZHAO X,ZHANG J.Mechanisms for quercetin in prevention of lung cancer cell growth and metastasis[J].Journal of Central South University(Medical Science),2015,40(6):592-597.
张敬,史晓宇,孟玮,等.山萘酚通过下调ERRα抑制非小细胞肺癌A549细胞的侵袭和迁移[J].中国肿瘤生物治疗杂志,2018,25(12):1230-1236.
ZHANG J,SHI X Y,MENG W,et al.Kaempferol inhibits invasion and migration of non-small cell lung cancer A549 cells by down-regulating ERRα expression[J].Chinese Journal of Cancer Biotherapy,2018,25(12):1230-1236.
仇炜,赵娟,吕雨虹,等.山奈酚诱导人小细胞肺癌H446细胞凋亡及机制[J].中国药理学通报,2011,27(10):1422-1425.
QIU W,ZHAO J,LYU Y H,et al.Kaempferol-induced apoptosis in human small cell lung cancer H446 cells[J].Chinese Pharmacological Bulletin,2011,27(10):1422-1425.
李爱明,赵惠民,揭俊卿.芒柄花黄素对非小细胞肺癌A549细胞增殖及上皮间质转化的抑制作用[J].临床肿瘤学杂志,2015,20(6):481-486.
LI A M,ZHAO H M,JIE J Q.Inhibitory effect of formononetin on proliferation and epithelial mesenchymal transition of non-small cell lung cancer A549 cells[J].Chinese Clinical Oncology,2015,20(6):481-486.
LI Q,REN F Q,YANG C L,et al.Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo[J].Asian Pac J Cancer Prev,2015,16(7):3035-3042.
周立霞,关洪全,马贤德,等.毛蕊异黄酮对肺腺癌细胞增殖和迁移功能的影响[J].辽宁中医杂志,2019,46(7):1474-1477+1567.
ZHOU L X,GUAN H Q,MA X D,et al.Calycosin inhibits biological function of lung cancer cells[J].Liaoning Journal of Traditional Chinese Medicine,2019,46(7):1474-1477+1567.
张乔,张琦,李静.黄芪甲苷抗肿瘤作用研究进展[J].中医药信息,2019,36(1):129-132.
ZHANG Q,ZHANG Q,LI J.Anti-tumor effects of astragaloside Ⅳ: Research progress study[J].Information on Traditional Chinese Medicine,2019,36(1):129-132.
陈晓萍,张长林.白术不同化学成分的药理作用研究概况[J].中医药信息,2011,28(2):124-126.
CHEN X P,ZHANG C L.Pharmacological effects profiles of different chemical composition of Atractylodes[J].Information on Traditional Chinese Medicine,2011,28(2):124-126.
YOO J K,JUNG H Y,LEE J M,et al.The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting AKT1[J].Cell Death Differ,2014,21(7):1150-1159.
王嘉,吕艳超,许浩然,等.非小细胞肺癌组织中AKT1、PDCD4蛋白表达变化及意义[J].山东医药,2016,56(6):16-18.
WANG J,LYU Y C,XU H R,et al.Expression changes of AKT1 and PDCD4 in non-small-cell lung cancer tissues and the significance[J].Shandong Medical Journal,2016,56(6):16-18.
FOLKMAN J.Tumor angiogenesis: therapeutic implications.[J].Pubmed,1971,285(21):1182-1186.
赵伟,马英,孔申嘉,等.FGF2、VEGFA表达水平与非小细胞肺癌转移的相关性分析[J].解放军医药杂志,2020,32(1):34-37.
ZHAO W,MA Y,KONG S J,et al.Correlations between expressions of FGF2 and VEGFA with metastasis of non-small-cell lung carcinoma[J].Medical & Pharmaceutical Journal of Chinese People's Liberation Army,2020,32(1):34-37.
董宏超,翟校枫.VEGFA-VEGFR2相关信号蛋白作用机制的研究进展[J].现代肿瘤医学,2014,22(9):2231-2233.
DONG H C,ZHAI X F.The research progress on the mechanism of tumor angiogenesis-related signal proteins[J].Journal of Modern Oncology,2014,22(9):2231-2233.
杨婧如,毕明宏.非小细胞肺癌抗血管生成治疗研究进展[J].现代肿瘤医学,2019,27(1):165-171.
YANG J R,BI M H.Recent development of anti-angiogenetic therapy in non-small cell lung cancer[J].Journal of Modern Oncology,2019,27(1):165-171.
谢一利,楼丽广.表皮生长因子受体信号通路及其靶向肿瘤治疗[J].国外医学(肿瘤学分册),2005(5):361-364.
XIE Y L,LOU L G.The epidermal growth factor receptor signal path and targeted cancer treatment[J].Foreign Medical Sciences ·Cancer Section,2005(5):361-364.
张伊,杨林,魏立彬.ROS-AMPK信号通路在肿瘤发生发展中的关系[J].世界最新医学信息文摘,2019,19(99):45-47+49.
ZHANG Y,YANG L,WEI L B.The role of Ros-ampk signaling pathway in tumorigenesis and development[J].World Latest Medicine Information,2019,19(99):45-47+49.
CHIO I I C,TUVESON D A.ROS in cancer:the burning question[J].Trends in Molecular Edicine,2017,23(5):411-429.
PARK J H,KIM T Y,JONG H S,et al.Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-α in gastric cancer cells[J].Clinical Cancer Research,2003,9(1):433-440.
OBZEN T.Oxidative stress and apoptosis:Impact on cancer therapy[J].Journal of Pharmaceutical Sciences,2007,96(9):2181-2196.
黄锐,陈琦.PI3K/Akt信号转导通路对肿瘤的影响[J].医学理论与实践,2016,29(19):3324-3327.
HUANG R,CHEN Q.Effect of PI3K/Akt signal transduction pathway on tumor[J].The Journal of Medical Theory and Practice,2016,29(19):3324-3327.
张雅雅.通过调控PI3K/Akt信号通路增强人肺癌顺铂耐药细胞对顺铂敏感性的研究[D].合肥:安徽医科大学,2016.
ZHANG Y Y.Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells[D].Hefei:Anhui Medical University,2016.
王丽萍.非小细胞肺癌的靶向和免疫治疗进展[J].郑州大学学报(医学版),2020,55(2):176-182.
WANG L P. Advances in targeted therapy and immunotherapy of non-small cell lung cancer[J].Journal of Zhengzhou University(Medical Sciences),2020,55(2):176-182.
0
浏览量
1
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构